Works matching IS 01676997 AND DT 2012 AND VI 30 AND IP 2
Results: 49
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 672, doi. 10.1007/s10637-010-9625-x
- By:
- Publication type:
- Article
New Vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 594, doi. 10.1007/s10637-010-9621-1
- By:
- Publication type:
- Article
Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms—action of two new agents.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 582, doi. 10.1007/s10637-010-9620-2
- By:
- Publication type:
- Article
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 662, doi. 10.1007/s10637-010-9604-2
- By:
- Publication type:
- Article
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 794, doi. 10.1007/s10637-010-9618-9
- By:
- Publication type:
- Article
Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 568, doi. 10.1007/s10637-010-9614-0
- By:
- Publication type:
- Article
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 846, doi. 10.1007/s10637-010-9612-2
- By:
- Publication type:
- Article
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 779, doi. 10.1007/s10637-010-9611-3
- By:
- Publication type:
- Article
The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 558, doi. 10.1007/s10637-010-9610-4
- By:
- Publication type:
- Article
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 787, doi. 10.1007/s10637-010-9615-z
- By:
- Publication type:
- Article
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 833, doi. 10.1007/s10637-010-9603-3
- By:
- Publication type:
- Article
Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 548, doi. 10.1007/s10637-010-9601-5
- By:
- Publication type:
- Article
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 828, doi. 10.1007/s10637-010-9599-8
- By:
- Publication type:
- Article
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 772, doi. 10.1007/s10637-010-9598-9
- By:
- Publication type:
- Article
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 541, doi. 10.1007/s10637-010-9597-x
- By:
- Publication type:
- Article
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 529, doi. 10.1007/s10637-010-9594-0
- By:
- Publication type:
- Article
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 819, doi. 10.1007/s10637-010-9593-1
- By:
- Publication type:
- Article
Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 765, doi. 10.1007/s10637-010-9592-2
- By:
- Publication type:
- Article
The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 810, doi. 10.1007/s10637-010-9586-0
- By:
- Publication type:
- Article
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 524, doi. 10.1007/s10637-010-9585-1
- By:
- Publication type:
- Article
Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 518, doi. 10.1007/s10637-010-9584-2
- By:
- Publication type:
- Article
Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 508, doi. 10.1007/s10637-010-9578-0
- By:
- Publication type:
- Article
A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 490, doi. 10.1007/s10637-010-9577-1
- By:
- Publication type:
- Article
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 480, doi. 10.1007/s10637-010-9576-2
- By:
- Publication type:
- Article
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 758, doi. 10.1007/s10637-010-9575-3
- By:
- Publication type:
- Article
Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 653, doi. 10.1007/s10637-010-9574-4
- By:
- Publication type:
- Article
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 749, doi. 10.1007/s10637-010-9573-5
- By:
- Publication type:
- Article
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 468, doi. 10.1007/s10637-010-9572-6
- By:
- Publication type:
- Article
Perirenal hematoma associated with bevacizumab treatment.
- Published in:
- 2012
- By:
- Publication type:
- Report
Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts.
- Published in:
- 2012
- By:
- Publication type:
- Report
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 611, doi. 10.1007/s10637-010-9546-8
- By:
- Publication type:
- Article
A phase I study of continuous infusion cilengitide in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 604, doi. 10.1007/s10637-010-9537-9
- By:
- Publication type:
- Article
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 616, doi. 10.1007/s10637-010-9559-3
- By:
- Publication type:
- Article
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 695, doi. 10.1007/s10637-010-9541-0
- By:
- Publication type:
- Article
Treatment of bevacizumab-induced hypertension by amlodipine.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 702, doi. 10.1007/s10637-010-9549-5
- By:
- Publication type:
- Article
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 681, doi. 10.1007/s10637-010-9538-8
- By:
- Publication type:
- Article
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 708, doi. 10.1007/s10637-010-9553-9
- By:
- Publication type:
- Article
Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 688, doi. 10.1007/s10637-010-9539-7
- By:
- Publication type:
- Article
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 723, doi. 10.1007/s10637-010-9557-5
- By:
- Publication type:
- Article
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 629, doi. 10.1007/s10637-010-9563-7
- By:
- Publication type:
- Article
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 714, doi. 10.1007/s10637-010-9556-6
- By:
- Publication type:
- Article
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 639, doi. 10.1007/s10637-010-9565-5
- By:
- Publication type:
- Article
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 729, doi. 10.1007/s10637-010-9561-9
- By:
- Publication type:
- Article
Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 425, doi. 10.1007/s10637-010-9566-4
- By:
- Publication type:
- Article
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 443, doi. 10.1007/s10637-010-9569-1
- By:
- Publication type:
- Article
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 741, doi. 10.1007/s10637-010-9562-8
- By:
- Publication type:
- Article
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 435, doi. 10.1007/s10637-010-9568-2
- By:
- Publication type:
- Article
A phase I study of temsirolimus and metformin in advanced solid tumours.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 647, doi. 10.1007/s10637-010-9570-8
- By:
- Publication type:
- Article
Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 450, doi. 10.1007/s10637-010-9571-7
- By:
- Publication type:
- Article